TEL1 Stock Chart & Stats
€0.09
>-€0.01(-8.16%)
At close: 4:00 PM EDT
€0.09
>-€0.01(-8.16%)
Day’s Range― - ―
52-Week Range€0.08 - €0.21
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
€774.08M
Enterprise Value€6.90K
Total Cash (Recent Filing)€3.72B
Total Debt (Recent Filing)€969.22M
Price to Earnings (P/E)19.1
Beta0.40
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding9,329,999,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.72
Price to Sales (P/S)3.85
P/FCF Ratio-46.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.12Price Target Upside38.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€380.13M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability RecoveryThe 2025 rebound indicates renewed demand and improved operating performance across the pharmaceutical portfolio. If revenue growth and profitability persist, the recovery can strengthen internal funding capacity, support investment in commercialization, and rebuild earnings power over the next several quarters.
High Gross-Margin Business ModelPersistently high gross margins provide meaningful economic value from pharmaceutical products and create operating leverage as sales expand. This margin structure can help absorb commercial costs, support research and development, and preserve profitability if the company sustains product demand and market access.
Manageable LeverageFalling leverage reduces balance-sheet pressure and leaves the company with greater capacity to withstand business volatility. A sizable equity base relative to debt can also provide flexibility to fund operations and pursue product development without relying excessively on additional borrowing.
Bears Say
Weak Cash GenerationNegative operating and free cash flow suggests that reported earnings are not consistently converting into usable cash. If this pattern continues, the company may have less flexibility to fund research, commercialization, or other investments internally, increasing dependence on balance-sheet resources.
Volatile Earnings PerformanceLarge swings in profitability make the recent turnaround less proven and reduce confidence in near-term earnings durability. Continued volatility could complicate planning, weaken the consistency of shareholder returns, and limit the company’s ability to rely on a stable earnings base for long-term investment.
Low Return On EquityA low and recently negative return on equity shows that the company’s substantial equity base is not yet producing consistently strong shareholder returns. Unless profitability improves further, capital may remain underutilized, limiting the effectiveness of the otherwise manageable balance sheet.
Sihuan Pharmaceutical Holdings Group News
TEL1 FAQ
What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?
Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was €0.08 and its highest was €0.21 in the past 12 months.
What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?
Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is €774.08M.
When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?
Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 188 days.
How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?
Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Aug 26, 2026. The company reported €0.003 earnings per share for the quarter.
Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?
According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Undervalued.
Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?
Sihuan Pharmaceutical Holdings Group Ltd. does not currently pay dividends.
What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?
Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?
Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.
What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?
Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of €0.003 in its last earnings report. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?
Currently, no hedge funds are holding shares in DE:TEL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sihuan Pharmaceutical Holdings Group Ltd.
Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral vascular system, as well as segments for innovative medicine, generic medicine, and medical aesthetics which includes injectables, energy-based devices, and skincare solutions. The company operates primarily in the People's Republic of China, with some international presence.
TEL1 Stock 12 Month Forecast
Average Price Target
€0.12
▲(38.21% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―